These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8357159)

  • 41. Assessment of pre and post-thymectomy myasthenia gravis.
    Bokoliya SC; Patil SA
    Neurol Res; 2019 Mar; 41(3):275-281. PubMed ID: 30574849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autoimmune diseases involving nicotinic receptors.
    Lindstrom J
    J Neurobiol; 2002 Dec; 53(4):656-65. PubMed ID: 12436428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular anatomy of an autoantigen: T and B epitopes on the nicotinic acetylcholine receptor in myasthenia gravis.
    Manfredi AA; Protti MP; Bellone M; Moiola L; Conti-Tronconi BM
    J Lab Clin Med; 1992 Jul; 120(1):13-21. PubMed ID: 1377215
    [No Abstract]   [Full Text] [Related]  

  • 44. Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.
    Vrolix K; Fraussen J; Losen M; Stevens J; Lazaridis K; Molenaar PC; Somers V; Bracho MA; Le Panse R; Stinissen P; Berrih-Aknin S; Maessen JG; Van Garsse L; Buurman WA; Tzartos SJ; De Baets MH; Martinez-Martinez P
    J Autoimmun; 2014 Aug; 52():101-12. PubMed ID: 24439114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myasthenia gravis: an example of receptor disease.
    Conti-Tronconi BM; Fumagalli G; Scotti A; Brigonzi A; Sher E; Morgutti M; Clementi F
    Adv Biochem Psychopharmacol; 1980; 21():473-88. PubMed ID: 7376974
    [No Abstract]   [Full Text] [Related]  

  • 46. The thymus in myasthenia gravis: Site of "innate autoimmunity"?
    Cavalcante P; Le Panse R; Berrih-Aknin S; Maggi L; Antozzi C; Baggi F; Bernasconi P; Mantegazza R
    Muscle Nerve; 2011 Oct; 44(4):467-84. PubMed ID: 21922466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A simplified ELISA for anti-receptor antibodies in myasthenia gravis.
    Jailkhani BL; Asthana D; Jaffery NF; Kumar R; Ahuja GK
    J Immunol Methods; 1986 Jan; 86(1):115-8. PubMed ID: 3944465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aetiological factors in development of myasthenia gravis.
    Vincent A
    Adv Neuroimmunol; 1994; 4(4):355-71. PubMed ID: 7719616
    [No Abstract]   [Full Text] [Related]  

  • 49. Antibodies against the acetylcholine receptor also in nonmyasthenic autoimmune disease.
    Sundewall AC; Lefvert K
    Ann N Y Acad Sci; 1988; 540():525-7. PubMed ID: 3207283
    [No Abstract]   [Full Text] [Related]  

  • 50. Humoral pathogenesis of myasthenia gravis.
    Drachman DB; de Silva S; Ramsay D; Pestronk A
    Ann N Y Acad Sci; 1987; 505():90-105. PubMed ID: 2446560
    [No Abstract]   [Full Text] [Related]  

  • 51. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes.
    Marx A; Pfister F; Schalke B; Saruhan-Direskeneli G; Melms A; Ströbel P
    Autoimmun Rev; 2013 Jul; 12(9):875-84. PubMed ID: 23535159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional inhibition of acetylcholine receptors by antibodies in myasthenic sera.
    Hall ZW; Pizzighella S; Gu Y; Vicini S; Schuetze SM
    Ann N Y Acad Sci; 1987; 505():272-85. PubMed ID: 2446552
    [No Abstract]   [Full Text] [Related]  

  • 53. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies.
    Graus YF; de Baets MH; Parren PW; Berrih-Aknin S; Wokke J; van Breda Vriesman PJ; Burton DR
    J Immunol; 1997 Feb; 158(4):1919-29. PubMed ID: 9029134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis.
    Hayashi A; Shiono H; Ohta M; Ohta K; Okumura M; Sawa Y
    J Neuroimmunol; 2007 Sep; 189(1-2):163-8. PubMed ID: 17706794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pathological basis of thymoma-associated myasthenia gravis.
    Müller-Hermelink HK; Marx A; Geuder K; Kirchner T
    Ann N Y Acad Sci; 1993 Jun; 681():56-65. PubMed ID: 7689313
    [No Abstract]   [Full Text] [Related]  

  • 56. Myasthenia gravis.
    Marx A; Schultz A; Wilisch A; Nenninger R; Müller-Hermelink HK
    Verh Dtsch Ges Pathol; 1996; 80():116-26. PubMed ID: 9020569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-nicotinic receptor autoimmunity in myasthenia gravis. Establishment of specific T-helper cell lines and identification of sensitizing epitopes on the alpha-subunit.
    Hohlfeld R; Toyka K; Heininger K; Tzartos SJ; Walgrave SL; Protti P; Conti-Tronconi BM
    Monogr Allergy; 1988; 25():50-67. PubMed ID: 2459613
    [No Abstract]   [Full Text] [Related]  

  • 58. Transplantation of myasthenia gravis thymus to SCID mice.
    Schönbeck S; Padberg F; Marx A; Hohlfeld R; Wekerle H
    Ann N Y Acad Sci; 1993 Jun; 681():66-73. PubMed ID: 8357210
    [No Abstract]   [Full Text] [Related]  

  • 59. Reflections on the "intrathymic pathogenesis" of myasthenia gravis.
    Hohlfeld R; Wekerle H
    J Neuroimmunol; 2008 Sep; 201-202():21-7. PubMed ID: 18644632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function.
    Vincent A; Li Z; Hart A; Barrett-Jolley R; Yamamoto T; Burges J; Wray D; Byrne N; Molenaar P; Newsom-Davis J
    Ann N Y Acad Sci; 1993 Jun; 681():529-38. PubMed ID: 8395163
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.